Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 25 Sep 2023

Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug design approach

in Cancer Molecular Targets and Therapeutics

Shopnil Akash
Shabana Bibi
Partha Biswas
Nobendu Mukerjee
Dhrubo Ahmed Khan
Md. Nazmul Hasan
Nazneen Ahmeda Sultana
Md. Eram Hosen
Yousef A. Bin Jardan
Hiba-Allah Nafidi

Frontiers in Oncology

doi 10.3389/fonc.2023.1228865

6,283 views
20 citations

Original Research

Published on 22 Sep 2023

Development, quality, and influencing factors of colonoscopy in China: results from the national census in 2013 and 2020

in Cancer Molecular Targets and Therapeutics

Yun-Fei Jiao
Zhi-Yuan Cheng
Ye Gao
Chu-Ting Yu
Hui-Shan Jiang
Ting-Lu Wang
Ying Deng
Han Lin
Tian-Jiao Wang
Wei Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1276520

2,613 views
4 citations

Case Report

Published on 19 Sep 2023

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

in Cancer Molecular Targets and Therapeutics

Yamin Meng
Xiaodong Li
Lei Zhang
Minhua Ye

Frontiers in Oncology

doi 10.3389/fonc.2023.1129629

3,258 views
1 citation

Mini Review

Published on 15 Sep 2023

Beyond liver cancer, more application scenarios for alpha-fetoprotein in clinical practice

in Cancer Molecular Targets and Therapeutics

Chenyu Ma
Yuexinzi Jin
Yuhan Wang
Huaguo Xu
Jiexin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1231420

2,161 views
2 citations

Original Research

Published on 14 Sep 2023

LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473

in Cancer Molecular Targets and Therapeutics

Yuanjiao Zhang
Jiacheng Qian
Mingmei Jiang
Shu Yang
Lianxin Zhou
Qin Zhang
Liping Lin
Ye Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1269670

1,700 views
1 citation

Hypothesis and Theory

Published on 14 Sep 2023

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer

in Cancer Molecular Targets and Therapeutics

Joseph R. Scarpa
Giacomo Montagna
George Plitas
Amitabh Gulati
Gregory W. Fischer
Joshua S. Mincer

Frontiers in Oncology

doi 10.3389/fonc.2023.1267532

2,337 views
5 citations

Original Research

Published on 13 Sep 2023

System analysis based on the lysosome-related genes identifies HPS4 as a novel therapy target for liver hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Ke‐Jie He
Zhiqiang Nie

Frontiers in Oncology

doi 10.3389/fonc.2023.1221498

1,813 views
1 citation

Review

Published on 12 Sep 2023

Cellular senescence: a double-edged sword in cancer therapy

in Cancer Molecular Targets and Therapeutics

Shuai Xiao
Dongmin Qin
Xueyang Hou
Lingli Tian
Yeping Yu
Rui Zhang
Hao Lyu
Dong Guo
Xing-Zhen Chen
Cefan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2023.1189015

13,659 views
38 citations

Review

Published on 08 Sep 2023

Single domain Camelid antibody fragments for molecular imaging and therapy of cancer

in Cancer Molecular Targets and Therapeutics

Shulin Li
Sanne Johanna Maria Hoefnagel
Kausilia Krishnawatie Krishnadath

Frontiers in Oncology

doi 10.3389/fonc.2023.1257175

4,644 views
2 citations

Original Research

Published on 08 Sep 2023

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Kristina Breitenecker
Viola Hedrich
Franziska Pupp
Doris Chen
Eva Řezníčková
Gregor Ortmayr
Heidemarie Huber
Gerhard Weber
Lorenz Balcar
Matthias Pinter

Frontiers in Oncology

doi 10.3389/fonc.2023.1238883

3,148 views
4 citations

Original Research

Published on 07 Sep 2023

CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage

in Cancer Molecular Targets and Therapeutics

Takeshi Hori
Kosuke Yokobori
Rick Moore
Masahiko Negishi
Tatsuya Sueyoshi

Frontiers in Oncology

doi 10.3389/fonc.2023.1217847

1,885 views
3 citations

Original Research

Published on 06 Sep 2023

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

in Cancer Molecular Targets and Therapeutics

Shan Jiang
Xinzhou Deng
Ming Luo
Le Zhou
Jingjing Chai
Chao Tian
Yutao Yan
Zhiguo Luo

Frontiers in Oncology

doi 10.3389/fonc.2023.1207081

3,380 views
7 citations

Case Report

Published on 06 Sep 2023

Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome

in Cancer Molecular Targets and Therapeutics

Ying Zhang
Xiaolu Wang
Yuning Zhu
Chong Liang
Lijun Zhao
Qi Meng
Jiani C. Yin
Yuqian Shi
Fufeng Wang
Feng Qin

Frontiers in Oncology

doi 10.3389/fonc.2023.1222873

2,217 views

Original Research

Published on 06 Sep 2023

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer

in Cancer Molecular Targets and Therapeutics

Yan Yang
Yu Shao
Junjun Wang
Qianqian Cheng
Hanqi Yang
Yulong Li
Jing Liu
Yangyang Zhou
Zhengguang Zhou
Mingxi Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1185240

1,854 views
2 citations

Review

Published on 06 Sep 2023

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges

in Cancer Molecular Targets and Therapeutics

Patrycja Aleksandra Bukłaho
Joanna Kiśluk
Jacek Nikliński

Frontiers in Oncology

doi 10.3389/fonc.2023.1227657

5,740 views
4 citations

Original Research

Published on 01 Sep 2023

Cross-species evaluation of fibroblast activation protein alpha as potential imaging target for soft tissue sarcoma: a comparative immunohistochemical study in humans, dogs, and cats

in Cancer Molecular Targets and Therapeutics

Patricia Beer
Chantal Pauli
Martina Haberecker
Paula Grest
Erin Beebe
Daniel Fuchs
Enni Markkanen
Christiane Krudewig
Mirja Christine Nolff

Frontiers in Oncology

doi 10.3389/fonc.2023.1210004

3,124 views
1 citation